FDA · Enforcement

FDA announces warning letters to 30 telehealth companies over compounded GLP-1 marketing

FDA announced 30 warning letters addressing claims that could imply compounded GLP-1 products were the same as FDA-approved products or obscure the source of the compounded product.

Agency warnings legal stageMar 3, 2026 record dateUnited States jurisdiction

Open the primary-source record

Record status

Agency initiative announced

Agency: U.S. Food and Drug Administration
Action: Warning-letter initiative
Stage: Agency warnings
Last verified: Jul 10, 2026

Source-backed timeline

Status history

Mar 3, 2026Initiative announcedSource

Editorial boundary: Peptide Report summarizes the public source and preserves its procedural stage. This page does not convert an allegation, proposal, advisory discussion, or warning into a final legal conclusion.

Back to all Regulatory Watch records